FITCHBURG, MA--(Marketwire - October 6, 2008) - Arrhythmia Research Technology, Inc. (the
"Company") (
AMEX:
HRT) announced that its Board of Directors has authorized
the repurchase of up to $650,000 of the Company's common stock from time to
time, subject to prevailing conditions and price levels.
Any repurchases will be made in the open market, through negotiated or
block transactions, using the Company's existing general corporate funds.
The repurchase program replaces a previous inactive plan adopted in June of
2003 and may be modified, suspended or discontinued at any time.
As of September 30, 2008, the Company had 2,711,680 shares of common stock
outstanding.
The Company, through Micron, manufactures silver plated and non-silver
plated conductive resin sensors and distributes metal snaps used in the
manufacture of disposable ECG, EEG, EMS and TENS electrodes. Micron's NEM
division manufactures custom injection molded products for medical,
electronic, industrial and consumer applications. Micron's MIT division
provides end-to-end product life cycle management through a comprehensive
portfolio of value-added services such as design, engineering, prototyping,
manufacturing, machining, assembly and packaging. Micron's Leominster Tool
division provides high end mold design and manufacturing for the injection
molding industry. The Company's products also include proprietary
signal-averaging electrocardiography (SAECG) software used in the detection
of potentially lethal heart arrhythmias.
For more information please visit our websites:
http://www.arthrt.com
http://www.newenglandmolders.com
http://www.leominstertool.com
http://www.micronproducts.com
http://www.micronintegrated.com
Forward-looking statements made herein are based on current expectations of
the Company that involve a number of risks and uncertainties and should not
be considered as guarantees of future performance. The factors that could
cause actual results to differ materially include: interruptions or
cancellation of existing contracts, impact of competitive products and
pricing, product demand and market acceptance, risks, the presence of
competitors with greater financial resources than the Company, product
development and commercialization risks, changing economic conditions in
developing countries, and an inability to arrange additional debt or equity
financing. More information about factors that potentially could affect
the Company's financial results is included in the Company's filings with
the Securities and Exchange Commission, including its Annual Report on Form
10-K for the year ended December 31, 2007.
Contact Information: Contact:
David A. Garrison
(978) 345-5000
Website: http://www.arthrt.com